A New Target for Alzheimer’s
Researchers at ETH Zurich have identified a potential therapeutic target for Alzheimer’s disease by focusing on the enzyme GRK2. A study published in Cell Reports Medicine details how a novel chemical substance, dubbed “Compound 10,” prevents the formation of harmful enzyme aggregates in brain cells, effectively slowing disease progression and extending survival in mouse models.
The Toxic Cycle of GRK2 Aggregation
Led by Professor Ursula Quitterer, the research centers on the regulatory protein GRK2. While this enzyme normally helps cells manage stress and process signals, the study found that in patients with dementia, a significant portion of GRK2 becomes inactivated.
These inactive molecules cluster into aggregates that accumulate on the mitochondria. By blocking the pores of these energy-producing structures, the clumps starve the cell and induce stress. This process accelerates the production of amyloid beta—a protein fragment considered a main cause of Alzheimer’s. The result is a self-perpetuating loop: amyloid beta increases cellular stress, which triggers further GRK2 aggregation.
Compound 10: Restoring Cellular Energy
To break this cycle, the team developed several chemical candidates, identifying “Compound 10” as the most effective. In laboratory experiments and mouse models, the substance prevented GRK2 molecules from clumping together.
When Compound 10 was administered, mitochondrial function improved and amyloid beta accumulation decreased. Nerve cell survival rates rose, and the progression of typical dementia symptoms slowed. Beyond neurological benefits, the researchers observed positive systemic effects in the mice, including improved heart function and a reduction in signs of biological aging, such as the development of grey hair.
Two Decades of Longitudinal Research
This discovery is the result of research that began almost 20 years ago, which utilized human brain tissue samples originally collected at Ain Shams University Hospital in Cairo. Quitterer noted that the timeline for Alzheimer’s research is significantly longer than in fields like cancer research, as studies involving age-related cognitive decline require lengthy observation periods in animal models.
Current clinical treatments for Alzheimer’s are largely limited to managing symptoms or providing modest delays in progression. By targeting the GRK2 enzyme, the researchers hope to introduce a different mechanism of action that could eventually be used alongside existing therapies.
Translating Findings to the Clinic
With the basic research phase complete and a patent application filed for Compound 10, the focus for the ETH Zurich team has shifted toward finding a commercial partner. The objective is to transition the substance from laboratory testing toward the development of a viable clinical drug. While the results in mice are promising, the researchers emphasize that translating these findings into human medicine is a complex, long-term endeavor.
Summary of Findings
- New Target Identified: The enzyme GRK2, when inactivated and aggregated, contributes to mitochondrial dysfunction and amyloid beta production.
- Mechanism of Action: Compound 10 prevents GRK2 aggregation, preserving mitochondrial energy production and protecting nerve cells.
- Systemic Benefits: Beyond slowing dementia symptoms in mice, the compound showed potential anti-aging effects on heart health and physical appearance.
- Research Timeline: The study, published in Cell Reports Medicine, is the culmination of nearly 20 years of work involving human tissue samples and longitudinal studies in mice.